Morgan Stanley Jounce Therapeutics, Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.9 - $1.85 $1.38 Million - $2.85 Million	-1,538,000 Reduced 92.77%	119,925 $221,000
Q4 2022 Feb 14, 2023	SELL	$0.64 - $1.99 $13,134 - $40,840	-20,523 Reduced 1.22%	1,657,925 $1.84 Million
Q3 2022 Nov 14, 2022	BUY	$2.73 - $4.92 $132,475 - $238,747	48,526 Added 2.98%	1,678,448 $3.93 Million
Q2 2022 Oct 27, 2022	BUY	$2.8 - $7.67 $290,175 - $794,872	103,634 Added 6.79%	1,629,922 $4.94 Million
Q2 2022 Aug 15, 2022	BUY	$2.8 - $7.67 $290,175 - $794,872	103,634 Added 6.79%	1,629,922 $4.94 Million
Q1 2022 Oct 27, 2022	SELL	$6.01 - $8.54 $622,840 - $885,034	-103,634 Reduced 6.36%	1,526,288 $10.4 Million
Q1 2022 May 13, 2022	BUY	$6.01 - $8.54 $8.96 Million - $12.7 Million	1,490,895 Added 4212.4%	1,526,288 $10.4 Million
Q4 2021 Feb 14, 2022	BUY	$7.11 - $9.64 $83,101 - $112,672	11,688 Added 49.31%	35,393 $295,000
Q3 2021 Nov 15, 2021	BUY	$5.04 - $8.73 $119,473 - $206,944	23,705 New	23,705 $175,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.